LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Cerrado

SectorSanidad

31.14

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

31.14

Máximo

31.17

Métricas clave
By Trading Economics
Ingresos	-85K 53M
Ventas	4.2M 153M
P/B Media del Sector	17.124 49.8
BPA	0.68
Margen de beneficios	34.53
Empleados	182
EBITDA	612K 81M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+6.26% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	577M 3.5B
Apertura anterior	31.14
Cierre anterior	31.14

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 may 2026, 22:50 UTC

Ganancias

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 may 2026, 22:49 UTC

Ganancias

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 may 2026, 22:32 UTC

Ganancias

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 may 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 may 2026, 22:57 UTC

Charlas de Mercado

Ganancias

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 may 2026, 22:26 UTC

Ganancias

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 may 2026, 22:25 UTC

Ganancias

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 may 2026, 22:25 UTC

Ganancias

Aristocrat Leisure Interim Dividend A$0.50/Security

12 may 2026, 22:24 UTC

Ganancias

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 may 2026, 22:23 UTC

Ganancias

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 may 2026, 22:23 UTC

Ganancias

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 may 2026, 22:19 UTC

Ganancias

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 may 2026, 22:14 UTC

Ganancias

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 may 2026, 22:14 UTC

Ganancias

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 may 2026, 22:13 UTC

Ganancias

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 may 2026, 22:12 UTC

Ganancias

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 may 2026, 22:12 UTC

Ganancias

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 may 2026, 22:11 UTC

Ganancias

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 may 2026, 22:11 UTC

Ganancias

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 may 2026, 22:10 UTC

Ganancias

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 may 2026, 22:09 UTC

Ganancias

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 may 2026, 22:09 UTC

Ganancias

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 may 2026, 22:08 UTC

Ganancias

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 may 2026, 22:07 UTC

Ganancias

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 may 2026, 22:06 UTC

Ganancias

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 may 2026, 22:06 UTC

Ganancias

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 may 2026, 22:05 UTC

Ganancias

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 may 2026, 22:04 UTC

Ganancias

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 may 2026, 22:04 UTC

Ganancias

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 may 2026, 22:04 UTC

Ganancias

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

6.26% repunte

Estimación a 12 Meses

Media 33.1 USD 6.26%

Máximo 35 USD

Mínimo 31.5 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.